Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

TACROLIMUS

TACROLIMUS

Standard Dose
EQ 5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview TACROLIMUS is listed in Drugs@FDA under application 215012 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient TACROLIMUS Form and strength CAPSULE, EXTENDED RELEASE;ORAL - EQ 5MG BASE Sponsor CHENGDU Submission history Latest submission status date: 2025-09-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview TACROLIMUS is listed in Drugs@FDA under application 215012 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TACROLIMUS Form and strength CAPSULE, EXTENDED RELEASE;ORAL - EQ 5MG BASE Sponsor CHENGDU Submission history Latest submission status date: 2025-09-04 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.